Pluristem Therapeutics Inc. — Focus on Regenerative Medicine
Pluristem Therapeutics Inc. (NASDAQ: PSTI) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, hematological disorders and exposure to radiation.
According to The Sage Group, approximately 65,000-75,000 major amputations (above-the-knee and below-the-knee) are performed annually for CLI in the United States. About 3 million people in the U.S suffer from CLI and this is expected to increase if the prevalence of diabetes continues to increase. For Europe, an analysis published by The Sage Group in 2010 concluded that 3 million people in Western Europe have CLI where the largest numbers of citizens suffering from CLI are located in Germany (over 768,000), Italy (over 700,000), Spain, the UK and France. These five countries account for 78% of CLI in Western Europe. Reflecting the aging population, and the increasing rate of diabetes, this number is projected to grow to 4 million by 2030. According to The Sage Group (2018), Peripheral Artery Disease afflicts 41 to 54 million patients in India and 42 to 60 million in China.
More than a quarter of a billion people in the world have peripheral artery disease (PAD), and the global prevalence of PAD increased by 24% from 2000 to 2010, from 164 million to 202 million (Gerald Fowkes, BSc, MBChB, from the Centre for Population Health Sciences at the University of Edinburgh in Scotland). In addition, there are an estimated 150,000 ischemic amputations that occur annually in the U.S. which represents a true burden on the healthcare systems.
Market Potential HIP:
- Patients with hip fractures experience functional decline, institutionalization and increase morbidity and mortality; one in three patients dies within the first year after injury. Liu, Z., et al., Optimized clinical practice for superaged patients with hip fracture: significance of damage control and enhanced recovery program. Burns Trauma, 2019. 7: p. 21.
- In the US, the annual treatment costs of HIP fracture are between 10 to 15 billion dollars and are expected to rise as well. Mundi, R., et al., Design and execution of clinical trials in orthopaedic surgery. Bone Joint Res, 2014. 3(5): p. 161-8.
Essentially, Pluristem is developing powerful cell therapies, currently in late-stage clinical studies, that can be commercialized to reach patients who need innovative treatment options for currently unmet needs. Its placenta-derived, off-the-shelf products do not require genetic or tissue matching prior to administration and can be delivered in almost any clinical setting.
Benefits of Pluristem’s commercial scale, highest quality cell products include the fact that it uses the cell manufacturing patented technology that was developed by the company and is tightly controlled, completely automated…GPM certified facilities. A state-of-the-art, proprietary bioreactor system provides a 3D micro-environment for cells that mimics the human body condition and Pluristem has the ability to manufacture treatments for over 20,000 patients per placenta while controlling the conditions within its bioreactors to produce several unique patented products, each with high batch to batch consistency.
“We design distinct cell products to target a several indications and anticipate that a pipeline of differentiated products and indications will allow us to target large global markets. We are currently exploring new partnerships to advance our clinical development programs, while maintaining our strong commitment to current corporate, academic and government collaborations such as NASA, the Department of Defense and the U.S. Government,” said Pluristem President & CEO Yaky Yanay.
For information visit https://www.pluristem.comor, call +972-74-710-8600 or email info@pluristem.com.
